Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. News
  7. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Quote. Real-time Euronext Paris - 06/11 11:35:27 am
3.988 EUR   +2.55%
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : S.A. ("Novacyt :" or the "Company") COVID-19 Diagnostic Regulatory Update

04/06/2020 | 02:01am EDT

CNR (Institut Pasteur) approval in France

Ministry of Health approval in Thailand

Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the CNR (Centre National de Référence des Virus des Infections Respiratoires (dont la grippe)) of the Institut Pasteur, an internationally renowned centre for biomedical research with a goal of improving public health in France, has approved its COVID-19 test. The Company’s CE-Mark test is available for immediate distribution into the French market.

On 2 April 2020, Novacyt also received approval for its COVID-19 test from the Ministry of Health in Thailand.

Graham Mullis, Chief Executive Officer of Novacyt, commented:

“As an Anglo-French company, I am delighted that Novacyt is able to support both of its domestic markets in tackling this pandemic. The Institut Pasteur’s evaluation and approval of our COVID-19 test is an important validation and I am grateful to Atothis, our distribution partner in France, for its efforts in working with the centre. We look forward to supporting the French authorities in their COVID-19 testing requirements.”

The Primerdesign COVID-19 test has received accreditation from a number of leading global regulatory authorities, including Public Health England and the US Food and Drug Administration. In addition to the test currently being approved in the UK, the US, France, India, the Philippines, Argentina and Thailand, it is available in markets which directly accept CE-Mark accreditation without the need for further approval.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

About COVID-19

Researchers at the Chinese Centre for Disease Control and Prevention and their collaborators have sequenced the 2019 novel coronavirus (COVID-19) pathogen from patient samples and have found it to be genetically distinct from the severe acute respiratory syndrome (SARS) virus that caused an epidemic in 2002 and 2003, as well as from the Middle East respiratory syndrome (MERS) virus that was detected in 2012.


© Business Wire 2020
All news about NOVACYT
06/03NOVACYT  : Launches Two New COVID-19 Tests
MT
06/03NOVACYT  : Launch of two new PCR COVID-19 assays
PU
05/31NOVACYT  : Monthly statement on outstanding equity shares and voting rights
CO
05/26GLOBAL MARKETS LIVE : Amazon, Volkswagen, AstraZeneca, Aston Martin, Sony...
05/26NOVACYT  : Launch of VersaLab™ Portable
PU
05/26NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of VersaLab™ Portable
BU
05/21NOVACYT  : Government and Covid test supplier Novacyt row over £150m PCR contrac..
AQ
05/21NOVACYT  : DHSC Dispute Update
PU
05/21NOVACYT S.A. ("NOVACYT", THE "COMPAN : DHSC Dispute Update
BU
05/17LONDON STOCK EXCHANGE : Banks, industrial stocks drag FTSE 100 down; Diploma jum..
RE
More news
Financials
Sales 2020 312 M 377 M 377 M
Net income 2020 185 M 224 M 224 M
Net cash 2020 102 M 123 M 123 M
P/E ratio 2020 1,52x
Yield 2020 -
Capitalization 282 M 341 M 341 M
EV / Sales 2020 0,58x
EV / Sales 2021 0,38x
Nbr of Employees 110
Free-Float 99,2%
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 3,99 €
Spread / Highest target 42,9%
Spread / Average Target 22,9%
Spread / Lowest Target 2,81%
EPS Revisions
Managers and Directors
NameTitle
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
R. A. Trevor Chief Technology Officer
Lisa Henriet Director-Group Operations
Sector and Competitors
1st jan.Capitalization (M$)
NOVACYT-59.31%341
MODERNA, INC.109.49%87 874
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
LONZA GROUP AG16.32%54 656